Skip to content
2000
Volume 8, Issue 1
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

If the Pharmaceutical Industry were to align to broad metrics that objectively state each product’s “Safety Rating” two things would happen. First, Life Sciences companies would refocus dramatically on safety (followed by outcomes). Second, companies that have the highest aggregate “Safety Rating” would enjoy a significant competitive advantage. To achieve and maintain a high safety rating, the role of Safety officer needs to be elevated to the C –Suite.

Loading

Article metrics loading...

/content/journals/cds/10.2174/1574886311308010006
2013-02-01
2025-06-24
Loading full text...

Full text loading...

/content/journals/cds/10.2174/1574886311308010006
Loading

  • Article Type:
    Research Article
Keyword(s): disruptions; Drug safety; safety rating; ‘chief safety officer’
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test